Indian VFX Company Digikore Studios Prepares to Go Global
Digikore Studios, the Indian VFX company behind popular international titles like Thor: Love and Thunder and Black Panther: Wakanda Forever, is preparing to go global.
In its next phase of growth, the company is set to launch its initial public offering (IPO) after receiving approval from NSE EMERGE. The IPO is scheduled to open on September 25, 2023, and close on September 27. The size of the IPO is Rs 30.479 crore and the price band is between Rs 168-171.
Digikore Studios was founded in 2010 by Abhishek More, who had a passion for visual effects. The company started out as a 2D animation company, but quickly transitioned to VFX in 2010.
More’s journey with Digikore has been a roller coaster ride. He made many mistakes in the early years, but he was determined to make the company a success. In 2010, he managed to get his first VFX project, Titanic 3D, by emailing James Cameron directly. This project became his calling card and helped him bag other projects.
In 2013, More decided to expand into India and work on Bollywood projects. However, this turned out to be a big mistake. The revenues from Indian projects were lower and the company started losing money. In 2016, More made the tough decision to shut down the Bollywood business and focus on Hollywood again.
The COVID-19 pandemic was a major challenge for Digikore Studios, but the company was able to weather the storm and come out stronger. The boom in over-the-top (OTT) platforms has been one of the biggest drivers of growth for many VFX studios, including Digikore.
Today, Digikore Studios is a leading VFX company with over 400 employees. The company is headquartered in India, but it has a subsidiary in Canada. Digikore Studios plans to expand its operations in North America in the coming years, but the bulk of the work will continue to be done from India.
Digikore Studios is a shining example of an Indian company that has made a mark on the global stage. The company’s success is a testament to the talent and creativity of Indian VFX artists.
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.